Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) CFO Douglas W. Pagan sold 4,139 shares of the company’s stock in a transaction on Wednesday, July 5th. The stock was sold at an average price of $23.58, for a total transaction of $97,597.62. Following the completion of the transaction, the chief financial officer now directly owns 60,000 shares in the company, valued at $1,414,800. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.
Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) traded down 1.279% during midday trading on Monday, hitting $23.545. 151,752 shares of the company traded hands. Paratek Pharmaceuticals, Inc. has a 12-month low of $9.80 and a 12-month high of $25.95. The company’s market capitalization is $647.13 million. The stock’s 50-day moving average price is $22.18 and its 200 day moving average price is $18.43.
Paratek Pharmaceuticals (NASDAQ:PRTK) last issued its quarterly earnings results on Thursday, May 4th. The specialty pharmaceutical company reported ($1.14) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($1.20) by $0.06. The firm had revenue of $0.02 million for the quarter.
ILLEGAL ACTIVITY NOTICE: This piece of content was originally posted by WKRB News and is the sole property of of WKRB News. If you are reading this piece of content on another site, it was illegally stolen and reposted in violation of US & international copyright & trademark legislation. The original version of this piece of content can be viewed at https://www.wkrb13.com/markets/2285557/douglas-w-pagan-sells-4139-shares-of-paratek-pharmaceuticals-inc-prtk-stock.html.
Several hedge funds have recently modified their holdings of PRTK. Credit Suisse AG increased its stake in shares of Paratek Pharmaceuticals by 36.6% in the first quarter. Credit Suisse AG now owns 18,110 shares of the specialty pharmaceutical company’s stock worth $349,000 after buying an additional 4,853 shares during the period. Highbridge Capital Management LLC purchased a new stake in shares of Paratek Pharmaceuticals during the first quarter worth $749,000. Nexthera Capital LP increased its stake in shares of Paratek Pharmaceuticals by 50.0% in the first quarter. Nexthera Capital LP now owns 150,000 shares of the specialty pharmaceutical company’s stock worth $2,888,000 after buying an additional 50,000 shares during the period. Nicholas Investment Partners LP purchased a new stake in shares of Paratek Pharmaceuticals during the first quarter worth $583,000. Finally, Renaissance Technologies LLC increased its stake in shares of Paratek Pharmaceuticals by 275.9% in the first quarter. Renaissance Technologies LLC now owns 414,513 shares of the specialty pharmaceutical company’s stock worth $7,979,000 after buying an additional 304,249 shares during the period. 75.43% of the stock is owned by institutional investors.
A number of equities analysts have recently weighed in on PRTK shares. Zacks Investment Research raised shares of Paratek Pharmaceuticals from a “hold” rating to a “buy” rating and set a $24.00 price target on the stock in a research note on Thursday, April 20th. HC Wainwright upped their price target on shares of Paratek Pharmaceuticals from $33.00 to $36.00 and gave the company a “buy” rating in a report on Tuesday, April 11th. Guggenheim set a $38.00 price target on shares of Paratek Pharmaceuticals and gave the company a “buy” rating in a report on Tuesday, April 4th. BTIG Research upped their price target on shares of Paratek Pharmaceuticals from $47.00 to $56.00 and gave the company a “buy” rating in a report on Tuesday, April 4th. Finally, Cantor Fitzgerald set a $33.00 price target on shares of Paratek Pharmaceuticals and gave the company a “buy” rating in a report on Thursday, May 4th. One research analyst has rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus price target of $37.00.
Paratek Pharmaceuticals Company Profile
Paratek Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics based upon tetracycline chemistry. Its product candidates are the antibacterials omadacycline and sarecycline. Omadacycline is an antibiotic being developed for use as an empiric monotherapy option for patients suffering from serious, community-acquired bacterial infections.
This story was originally published by WKRB News (https://www.wkrb13.com) and is the sole property of WKRB News. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at https://www.wkrb13.com/markets/2285557/douglas-w-pagan-sells-4139-shares-of-paratek-pharmaceuticals-inc-prtk-stock.html
Receive News & Ratings for Paratek Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Paratek Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.